FIELD: biotechnology and immunology.
SUBSTANCE: polyspecific polypeptide construct is proposed for binding to CD3 and tumour-specific antigen (TAA), which has limited binding to CD3. A polynucleotide encoding a polyspecific polypeptide construct, an expression vector, a cell, a pharmaceutical composition and methods for producing and using polyspecific polypeptides for stimulating or inducing an immune response in a patient having a tumour or malignant neoplasm or treating a tumour or malignant neoplasm in a patient are also proposed.
EFFECT: proposed constructs do not demonstrate the ability to bind T cells when they are not associated with a TAA target, while maintaining a strong ability to induce antigen-dependent T cell cytotoxicity.
55 cl, 38 dwg, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2022 |
|
RU2824285C2 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
| TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING CROSSOVER FORMAT WITH DOUBLE VARIABLE DOMAIN (CODV) FOR TREATING INFECTION CAUSED BY HIV | 2020 |
|
RU2820164C2 |
| TRISPECIFIC BINDING PROTEINS BINDING CD38, CD28 AND CD3, AS WELL AS METHODS OF USE FOR TREATING VIRAL INFECTION | 2019 |
|
RU2820351C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
